6月9日，星昊医药盘中29.96%涨停，截至10:19，报25.72元/股，成交3.48亿元，换手率12.38%，总市值31.45亿元。
资料显示，北京星昊医药股份有限公司位于北京经济技术开发区中和街18号，公司专注于为全球医药行业提供新药和仿制药的定制研发与生产服务，涵盖从临床研究到药品上市的全生命周期。公司拥有多个研发及生产基地，并凭借其在缓控释制剂、复杂注射剂等领域的技术优势，已为百余家医药企业提供了创新药和仿制药的CMC/CMO服务。
截至9月30日，星昊医药股东户数7571，人均流通股1.04万股。
2024年1月-9月，星昊医药实现营业收入4.68亿元，同比减少9.91%；归属净利润7877.01万元，同比增长8.22%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.